Prospect Venture Partners β Full Portfolio
27 tracked investments Β· listed companies and verified rows first
Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
BiotechDigital HealthHealthtechMedical Devices
Amicus is a wholly owned subsidiary of BioMarin Pharmaceutical Inc., a global rare disease biotechnology company that develops medicines for people with genetically defined conditions.
BiotechHealthtechCranbury, US
Daphne Quimi(Executive Officer)Craig A. Wheeler(Director)Ted W. Love(Director)John Crowley(Executive Officer, Director)William D. Baird, III(Executive Officer)Margaret G. McGlynn(Director)
Acquired by Bristol Myers Squibb
PartnerRussell HirschΒ· led
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
HealthtechMountain View, US
William Sutton(Executive Officer)Christopher P. Lowe(Executive Officer, Director)Cary Vance(Executive Officer, Director)Robert Cathcart(Executive Officer)Brian Sheahan(Executive Officer)Joseph Guido(Executive Officer)
PartnerRussell HirschΒ· led
Seattle-based developer of software for managed care.
BiotechSan Diego, US
Steven J. Mento, Ph.D.(Director)David F. Hale(Executive Officer, Director)
BoardPaul Klingenstein(Director)Louis Lacasse(Director)James Scopa(Director)Shahzad Malik(Director)
Jazz Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases and cancers, with a focus on oncology and biomarker-driven therapies such as those targeting HER2-expressing cancers.
BiotechHealthtech
Acquired by Takeda Pharmaceutical
PartnerRussell HirschΒ· led
BiotechSouth San Francisco, US
Jin-Long Chen(Executive Officer, Director)David V. Goeddel(Director)William J. Rieflin(Executive Officer, Director)
BoardPeter Svennilson(Director)Mark Leschly(Director)David Schnell(Director)
Pharmaceutical company acquired by Alexion in 2020.
PartnerRussell HirschΒ· led
AtriCure develops medical devices and solutions for atrial fibrillation (Afib) treatment, focusing on patient care and early recognition of cardiac health changes.
BiotechMedical DevicesRedwood City, US
Victor Tong(Director)Russell Seiber(Executive Officer, Director)Theodore Huber(Director)Pam Simons(Executive Officer)Greg Fung(Executive Officer)Steven Hochberg(Director)
PartnerRussell HirschΒ· led
Acquired by Valeant via Medicis
Acquired by Emergent BioSolutions
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.